USA: Sterile Injectables Pfizer to Invest Nearly Half a Billion Dollars in Sterile Injectable Facility

Editor: Alexander Stark

Pfizer is investing $ 465 million to build a technically advanced sterile injectable pharmaceutical production facility in Portage, Michigan.

Related Vendors

Pfizer is going to build a cutting-edge sterile injectable facility in Michigan.
Pfizer is going to build a cutting-edge sterile injectable facility in Michigan.
(Source: Pfizer)

New York/USA — Known as Modular Aseptic Processing (MAP), the new, multi-story, 37,000-m2-production facility will also create an estimated 450 new jobs over the next several years. This expands the company’s presence in Portage, located in Kalamazoo County, where the company now employs more than 2,200 people at one of its largest plants.

Ian Read, Chairman and Chief Executive Officer, said that this investment was part of the company's overall plan announced in January to invest approximately $ 5 billion in US-based capital projects as a result of the enactment of the Tax Cuts and Jobs Act. During the next six years, he expects to invest approximately $ 1.1 billion in Kalamazoo County — which was in addition to the $ 1 billion the company invested in the site over the past decade.

Ron Perry, Site Leader for the Portage plant, said the new sterile injectable facility will strengthen the site’s role in Pfizer’s global network. Sterile drug product manufacturing was incredibly complex and this contemporary facility would combine cutting-edge technology and a highly talented workforce to assure the company remained a trusted and reliable supplier of these therapies to patients, he added.

MAP will incorporate technically advanced aseptic manufacturing equipment, systems and design, including multiple, self-contained modular manufacturing lines. This allows the manufacturing line in each module to be entirely separate from all other manufacturing lines. Groundbreaking is planned for spring 2019, with construction expected to be completed in 2021. After the facility is validated by regulatory agencies, production should begin in 2024.